About this trial
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.
Eligibility criteria
Qualifiers
mild or major neurocognitive disorder OR mild behavioural impairment
Apathy for at least 4 weeks
Stable dose of medication (>4 weeks) that may affect cognition or behaviour
Care partner who spends at least 10 hours a week with the subject
Disqualifiers
Current major depressive episode
Agitation, delusions, hallucination
Medical contraindications to rTMS
Currently taking an amphetamine product
Trial design
Treatments tested in this trial
- rTMS
- methylphenidate
Treatment groups
Locations
1Sponsors and collaborators
Sunnybrook Health Sciences Centre
Lead sponsor